Cosmos Pharmaceutical reports modest Q1 growth despite headwinds

For the three months ended August 31, 2025, Cosmos Pharmaceutical reported JPY 272,394m in net sales, marking a 4.0% increase year-on-year. Operating profit grew by 0.6% to JPY 11,645m, while ordinary profit saw a slight decrease of 0.9% to JPY 12,188m. Profit attributable to owners of parent increased by 0.3% to JPY 8,171m. The company continued its store expansion, opening 12 new stores and closing 1, bringing the total to 1,620 stores.

Total assets as of August 31, 2025, decreased by JPY 449m from the previous fiscal year-end, totaling JPY 524,305m. This was primarily due to a JPY 7,499m decrease in cash and deposits and a JPY 3,153m decrease in merchandise. Net assets increased by JPY 5,194m to JPY 262,658m, largely due to an increase in retained earnings.

The company maintains its consolidated financial results forecast for the fiscal year ending May 31, 2026. The annual dividend forecast for May 31, 2026, is JPY 75.00, with a projected year-end dividend of JPY 37.50.